Cargando…
Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications
Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although other forms of mesoporous silica have been in...
Autores principales: | Waters, Laura J., Hanrahan, John P., Tobin, Joseph M., Finch, Catherine V., Parkes, Gareth M.B., Ahmad, Shamsuddeen A., Mohammad, Faraj, Saleem, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Xi'an Jiaotong University
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004617/ https://www.ncbi.nlm.nih.gov/pubmed/29922487 http://dx.doi.org/10.1016/j.jpha.2018.01.004 |
Ejemplares similares
-
Serum protein expression in Equine Glandular Gastric Disease (EGGD) induced by phenylbutazone
por: TESENA, Parichart, et al.
Publicado: (2019) -
PLGA-modified Syloid(®)-based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations
por: Zaghloul, Nada, et al.
Publicado: (2022) -
Toward of Safer Phenylbutazone Derivatives by Exploration of Toxicity Mechanism
por: Borges, Rosivaldo S., et al.
Publicado: (2019) -
Effects of phenylbutazone, firocoxib, and dipyrone on the diuretic response to furosemide in horses
por: White, Julianne M., et al.
Publicado: (2023) -
Development and Characterization of Liquisolid Tablets Based on Mesoporous Clays or Silicas for Improving Glyburide Dissolution
por: Cirri, Marzia, et al.
Publicado: (2020)